To date, more than 20 genetic variants of monogenic MODY phenotypes have been identified, and a treatment strategy with insulin or its combination with glucose-lowering drugs from the sulfonylurea group has been defined for most forms (Supplementary Table S1). The gene discussed is INS; the disease is MODY.